Myeloid-Derived Suppressor Cells in Aged Humans
Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells whose
immunosuppressive activities contribute to cancer and other diseases. MDSCs
appear to increase with age, and this presumably contributes to immunosuppression
and the increased incidence of certain diseases. Why MDSCs increase with
age is not entirely clear. Herein we present evidence that MDSC expansion is due
in part to age-related changes in hematopoiesis, including the acquisition of
mutations that favor myelopoiesis, which are compounded by changes in the
aging microenvironment that favor the production of MDSCs.
Congratulations to the newly minted Dr. Loukov on successfully defending her thesis entitled “Age-Associated Inflammation impairs Myeloid Development and Monocyte & Macrophage Function”!
The newly minted Dr. Loukov drinks from the chalice.
Dessi celebrates her thesis defence with one of her mentors Dr. Mark McDermott.
The Bowdish lab would like to congratulate our latest MSc, Grace Teskey on a great MSc defence. Congratulations Grace!
Grace drinks from the chalic after defending her MSc.
Grace’s words of wisdom.
Dr. Dawn Bowdish and her PhD student Dessi Loukov collaborated with Dr. Monica Maly and Sara Karampatos (Rehabilitation Science) and found that monocytes were more activated and pro-inflammatory in women with osteoarthritis, and that elevated inflammation and body mass index were associated with increased monocyte activation. Further, the team found that women with osteoarthritis and more activated monocytes experienced worse pain than individuals with less activated monocytes. These findings highlight the importance of modulating inflammation and body mass to manage osteoarthritis and open up new avenues for therapeutic research.
Read the full publication in the Osteoarthritis Research Society International (OARSI) Journal
As featured in Eureka Alert: https://www.eurekalert.org/pub_releases/2017-11/mu-rul112717.php
Click here to hear Dawn’s interview with Radio Canada on our recent paper on the role of the microbiome in age-associated inflammtion…
We’re thrilled that our publication was featured as an editorial in Cell Host & Microbe. Read Drs Erin S. Keebaugh and William W. Ja’s excellent editorial here…..
Antibiotic treatment alone may not be sufficient to treat pneumonia in older adults. In fact, it appears as though the inflammation that comes naturally with age increases the risk of developing pneumonia. “It sounds counterintuitive to limit inflammatory responses during a bacterial infection, but clinical observations and our research indicates anti-bacterial strategies need to be tailored to the age of the patient,” said MIRC’s Associate Professor Dawn Bowdish.
Aging is accompanied by a chronic state of low-level inflammation — sometimes called ‘inflamm-aging’ — which is associated with diseases such as cardiovascular disease, dementia and infections, particularly pneumonia. Upon recognition of an infectious agent, an acute inflammatory response is required to fight infection and resolves shortly after. However, in older adults, where systemic inflammation is already elevated, increases in inflammation during infection do not resolve as quickly. Exposure to these high levels of inflammation appears to impair the ability of monocytes and macrophages to fight infection.
Published today in the journal PLoS Pathogens, MIRC graduate Dr. Alicja Puchta & PhD student Avee Naidoo demonstrated that the higher levels of inflammation in the blood of old mice caused the premature egress of inflammatory monocytes into the blood stream, and contributed to greater systemic inflammation. Although small amounts of inflammation are required to fight infection, enhanced production of inflammation in old mice lead to reduced monocyte and macrophage function. Reducing levels of inflammation in the young mice had no effect but reducing levels in the old mice resulted in improved bacterial clearance and survival against S.pneumoniae.
The research follows a 2015 McMaster study that showed that older adults with pneumonia do better when given drugs, such as corticosteroids, to reduce inflammation in addition to antibiotics. “Our study in mice is consistent with clinical studies that recommend using anti-inflammatories as part of treatment to improve older adults’ defence against pneumonia, and that points to the development of better care,” said Bowdish.
To read the PLoS Pathogens article, please click here.